Premiere Date: August 20, 2019
Expiration Date: February 20, 2021
This activity offers CE credits for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
The goal of this activity is to provide an understanding of the mechanisms involved in the innervating effects of caffeine and the impact that caffeine may have on psychiatric disorders.
At the end of this CE activity, participants should be able to:
• Discuss the pharmacokinetics of caffeine
• Explain the adenosine-dependent modulation of striatal dopamine and glutamate neurotransmission
• Describe the adenosine-dependent modulation of glutamate neurotransmission in the amygdala
• Recount the implications of caffeine on anxiety
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Sergi Ferré, MD, PhD, has no disclosures to report.
Cyril Willson (peer/content reviewer), has no disclosures to report.
John J. Miller, MD (peer/content reviewer), has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
For content-related questions, email us at [email protected]; for questions concerning CME credit call us at 877.CME.PROS (877.263.7767)
Dr Ferré is Senior Scientist and Chief of the Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD.
1. Weinberg BA, Bealer BK. The World of Caffeine: The Science and Culture of the World’s Most Popular Drug. New York, London: Routledge; 2001.
2. Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 2018;70:384-411.
3. Cozza KL, Armstrong SC, Oesterheld JR. Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, IGTs, P-Glycoproteins, 2nd ed. Washington, DC; American Psychiatric Publishing; 2003.
4. Ferré S. Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacol. 2016;233:1963-1979.
5. Ferré S, Bonaventura J, Zhu W, et al. Essential control of the function of the striatopallidal neuron by pre-coupled complexes of adenosine A(2A)-dopamine D(2) receptor heterotetramers and adenylyl cyclase. Front Pharmacol. 2018;9:243.
6. Navarro G, Cordomí A, Casadó-Anguera V, et al. Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase. Nat Commun. 2018;9:1242.
7. Navarro G, Cordomí A, Brugarolas M, et al. Cross-communication between G(i) and G(s) in a G-protein-coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC Biol. 2018;16:24.
8. Rau AR, Ariwodola OJ, Weiner JL. Presynaptic adenosine A1 receptors modulate excitatory transmission in the rat basolateral amygdala. Neuropharmacol. 2014;77:465-74.
9. Rau AR, Ariwodola OJ, Weiner JL. Postsynaptic adenosine A2A receptors modulate intrinsic excitability of pyramidal cells in the rat basolateral amygdala. Int J Neuropsychopharmacol. 2015;18:1-13.
10. Simões AP, Machado NJ, Gonçalves N, et al. Adenosine A(2A) Receptors in the amygdala control synaptic plasticity and contextual fear memory. Neuropsychopharmacol. 2016;41:2862-2871.
11. Shinohara M, Saitoh M, Nishizawa D, et al. ADORA2A polymorphism predisposes children to encephalopathy with febrile status epilepticus. Neurology. 2013;80:1571-1576.
12. Hamilton SP, Slager SL, De Leon AB, et al. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacol. 2004;29:558-565.
13. Childs E, Hohoff C, Deckert J, et al. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacol. 2008;33:2791-2800.
14. Quiroz C, Orrú M, Rea W, et al. Local control of extracellular dopamine levels in the medial nucleus accumbens by a glutamatergic projection from the infralimbic cortex. J Neurosci. 2016;36:851-859.
15. Lammel S, Lim BK, Ran C, et al. Input-specific control of reward and aversion in the ventral tegmental area. Nature. 2012;491:212-217.
16. LeDoux JE, Moscarello J, Sears R, et al. The birth, death and resurrection of avoidance: a reconceptualization of a troubled paradigm. Mol Psychiatry. 2017;22:24-36.
17. Orrú M, Guitart X, Karcz-Kubicha M, et al. Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacol. 2013;67:476-484.
18. Schiffmann SN, Fisone G, Moresco R, et al. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007;83:277-292. ❒